Hepatic stellate cell pro-fibrotic signaling pathways (HSC pro-fibrotic pathways)

Hepatic stellate cells (HSCs) are the primary drivers of liver fibrosis, undergoing a phenotypic transformation from quiescent vitamin A-storing cells to activated, myofibroblast-like cells in response to chronic injury (Friedman, 2008, Physiological Reviews). This activation is mediated by a complex network of pro-fibrotic signaling pathways, most notably the Transforming Growth Factor-beta (TGF-beta) pathway, which is the most potent inducer of extracellular matrix (ECM) production (Meng et al., 2016, Nature Reviews Nephrology). Other critical pathways include Platelet-Derived Growth Factor (PDGF) signaling, which drives HSC proliferation, and various chemokine-mediated pathways (e.g., CCR2/CCR5) that promote HSC recruitment and inflammation (Tsuchida & Friedman, 2017, Cell Metabolism). These signals trigger increased proliferation, chemotaxis, and the massive production of ECM proteins like collagen, leading to tissue scarring and eventually cirrhosis. Therapeutic strategies targeting these pathways aim to inhibit HSC activation, promote their reversion to a quiescent state, or induce apoptosis in activated cells to halt or reverse fibrotic progression (Puche et al., 2013, Comprehensive Physiology). Because this entry describes a broad biological process and network of multiple distinct proteins rather than a single molecular target, it is classified as a pathway-level description.

Other names

Hepatic stellate cell activation pathwaysHSC signaling networkLiver fibrogenesis signalingMyofibroblast transformation pathways

Inhibition of pro-fibrotic cytokine signaling (e.g., TGF-beta), blockade of growth factor receptors (e.g., PDGFR), and modulation of intracellular signaling cascades (e.g., MAPK, ASK1) to prevent myofibroblast activation and extracellular matrix deposition (Tsuchida & Friedman, 2017, Cell Metabolism).